In recent years, the discovery of the fourth-generation inhibitors to specifically inhibit the triple EGFR mutants responsible for the resistance to second- and third-generation inhibitor drugs has become the focus of anti-NSCLC drug development [30]. Here, EGFR is linked to non-small cell lung carcinoma.